These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 17269594

  • 1. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
    Mochizuki T, Naganuma S, Tanaka Y, Iwamoto Y, Ishiguro C, Kawashima Y, Maekawa K, Suda A, Akiba T, TWMU Renal Osteodystrophy Study Group.
    Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, Nakamura R, Monkawa T, Ichihara A.
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [Abstract] [Full Text] [Related]

  • 3. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M.
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
    Honda H, Koiwa F, Ogata H, Shishido K, Sekiguchi T, Michihata T, Ogawa H, Mukai M, Takahashi K, Suzuki R, Kino K, Kato K, Yamamoto K, Kinugasa E, Akizawa T.
    Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Nephron Clin Pract; 2006 May; 102(1):c1-7. PubMed ID: 16166800
    [Abstract] [Full Text] [Related]

  • 7. [The clinical evaluation of maxacalcitol on therapy for secondary hyperparathyroidism of chronic hemodialysis patients].
    Kasai K, Abe R, Wakabayashi M, Nakamura K, Sawatani S, Wakabayashi T.
    Nihon Jinzo Gakkai Shi; 2002 May; 44(5):464-70. PubMed ID: 12216479
    [Abstract] [Full Text] [Related]

  • 8. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S, Wazny LD, Martin JE.
    Can J Clin Pharmacol; 2008 May; 15(1):e36-43. PubMed ID: 18192704
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Oyama Y, Kazama JJ, Omori K, Higuchi N, Kameda S, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F.
    Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
    [Abstract] [Full Text] [Related]

  • 10. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 11. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y.
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [Abstract] [Full Text] [Related]

  • 12. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R, Naito S, Inagaki Y, Hata T, Ishida Y, Chida Y, Takayama M, Tachibana K, Ohtsuka M, Inoue A.
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [Abstract] [Full Text] [Related]

  • 13. [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
    Yamada Y, Kumafuji M, Sodeyama T, Suzawa T, Momose M, Tokoo M.
    Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647
    [Abstract] [Full Text] [Related]

  • 14. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, Mohamad S, Goh BL, Shah S, Seman MR, Vaithilingam I, Ghazalli R, Rahmat K, Shaariah W, Ching CH, Oral Paricalcitol in ESRD Study Group.
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [Abstract] [Full Text] [Related]

  • 15. [A case with secondary hyperparathyroidism suggesting the direct suppressive effect of maxacalcitol on osteoblasts].
    Shiota J, Tanaka A.
    Nihon Jinzo Gakkai Shi; 2002 Mar; 44(5):471-5. PubMed ID: 12216480
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E.
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [Abstract] [Full Text] [Related]

  • 17. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Kazama JJ, Omori K, Higuchi N, Takahashi N, Ito Y, Maruyama H, Narita I, Cantor TL, Gao P, Gejyo F.
    Nephrol Dial Transplant; 2004 Apr; 19(4):892-7. PubMed ID: 15031346
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, Takahashi K, Ota K, Fujii H, Ueda S, Nishi S, Nakatani T, Yoshiyama M, Goto K, Hamada T, Imanishi M, Ishimura E, Kagitani S, Kato Y, Kumeda Y, Maekawa K, Matsumura T, Nagayama H, Obi Y, Ohno Y, Sai Y, Sakurai M, Sasaki S, Shidara K, Shoji S, Tsujimoto Y, Yamakawa K, Yasuda H, Yodoi S, Inaba M, Emoto M.
    Clin J Am Soc Nephrol; 2021 Apr 07; 16(4):599-612. PubMed ID: 33685864
    [Abstract] [Full Text] [Related]

  • 19. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS, Quarles LD.
    Kidney Int; 2000 Jan 07; 57(1):282-92. PubMed ID: 10620210
    [Abstract] [Full Text] [Related]

  • 20. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.
    Clin Nephrol; 2009 Jun 07; 71(6):660-8. PubMed ID: 19473635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.